×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IKT – inhibikase therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IKT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
03:34 pm
ikt
Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 [Seeking Alpha]
Low
Report
Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 [Seeking Alpha]
11/14
08:37 am
ikt
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Low
Report
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
11/8
08:46 am
ikt
Inhibikase Therapeutics, Inc. (NYSE: IKT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.
High
Report
Inhibikase Therapeutics, Inc. (NYSE: IKT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.
10/21
09:09 am
ikt
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension [Yahoo! Finance]
10/21
09:05 am
ikt
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
Medium
Report
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
10/14
01:44 pm
ikt
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its price target lowered by analysts at HC Wainwright from $15.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its price target lowered by analysts at HC Wainwright from $15.00 to $5.00. They now have a "buy" rating on the stock.
10/9
09:18 am
ikt
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
Medium
Report
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
Date
Time
Symbol
Company Name
Action
%Chg
11/14/2024
08:37 am
ikt
inhibikase therapeutics, inc.
MISS
Report
-2.5%
inhibikase therapeutics, inc.
8/14/2024
04:25 pm
ikt
inhibikase therapeutics, inc.
MISS
Report
-5.4%
inhibikase therapeutics, inc.
5/15/2024
05:04 pm
ikt
inhibikase therapeutics, inc.
BEAT
Report
-5.9%
inhibikase therapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/18
04:49 pm
ikt
Form S-3 Inhibikase Therapeutics,
Low
Report
Form S-3 Inhibikase Therapeutics,
11/18
04:05 pm
ikt
Form DEF 14A Inhibikase Therapeutics, For: Jan 03
Low
Report
Form DEF 14A Inhibikase Therapeutics, For: Jan 03
11/14
03:31 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G Inhibikase Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
11/14
08:31 am
ikt
Form 10-Q Inhibikase Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Inhibikase Therapeutics, For: Sep 30
11/8
04:10 pm
ikt
Form PRE 14A Inhibikase Therapeutics, For: Jan 03
High
Report
Form PRE 14A Inhibikase Therapeutics, For: Jan 03
10/28
05:27 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: SP IKT Holdings LLC
Low
Report
Form SC 13G Inhibikase Therapeutics, Filed by: SP IKT Holdings LLC
10/28
04:01 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: Soleus Private Equity Fund III, L.P.
Medium
Report
Form SC 13G Inhibikase Therapeutics, Filed by: Soleus Private Equity Fund III, L.P.
10/25
05:53 pm
ikt
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.
High
Report
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: